Imagine your lungs are like sponges that become stiff and scarred, making it hard to breathe. Current medicines only slow this down, but often make patients feel sick. This project is creating a new drug that stops the scarring process at the very start, potentially allowing the lungs to heal themselves.
Current IPF treatments do not cure the disease and are often discontinued by over 40% of patients due to severe side effects. There is a massive unmet need for a well-tolerated, potentially curative therapy.
A drug candidate, OXC-201, and the associated preclinical safety and efficacy data required for human clinical trials.
If you are a large pharmaceutical company dealing with a lack of curative IPF treatments — this project developed OXC-201 that targets inflammation and fibrosis to potentially halt disease progression.
If you are a drug development firm dealing with high patient dropout rates in lung therapy — this project developed a candidate with improved safety and tolerability in preclinical models.
If you are a pulmonary clinic dealing with patients who stop treatment within the first year due to side-effects — this project developed a therapy aimed at being better tolerated than current standards.
Based on available project data, the specific cost of OXC-201 is not mentioned, though it is noted that current market therapies are very costly.
Based on available project data, the project is currently moving toward first-in-human clinical studies and is not yet at industrial scale.
The end goal is to bring OXC-201 to market via a licensing deal with a large pharmaceutical company.
The project is preparing the Investigational Medicinal Product Dossier (IMPD), Clinical Trial Application (CTA), and ethical applications to initiate human studies.
The project period runs from 2023-05-01 to 2026-08-31, during which first-in-human clinical studies will be performed.
The project is led by a single Swedish SME, OXCIA AB, representing a 100% industry ratio. This lean structure suggests a focused, agile approach to drug development, aiming for a high-value exit via licensing to a larger pharmaceutical entity.
Contact OXCIA AB in Sweden regarding OXC-201 licensing
Connect with OXCIA AB to explore early-stage licensing opportunities for OXC-201.
